Avalyn Pharma Inc. Chief Medical Officer Howard Lazarus exercised options for 13,300 shares of common stock at $4.62 per share on November 17, 2026. He sold 13,300 shares that day in three reported transactions: 11,023 at a weighted-average price of $27.8001, 2,066 at $28.2722, and 211 at $29.2722 per share. The exercise and sales were made pursuant to a Rule 10b5-1 trading plan adopted on July 30, 2026. The option record reported 257,198 underlying shares following exercise; the option expires January 24, 2034.
Avalyn Pharma Inc. (AVLN) Chief Executive Officer Lyn Baranowski exercised options for 52,500 shares of common stock at an option exercise price of $4.62 per share on November 17 and 18, 2026, and sold 52,500 shares in multiple transactions on those dates. The transactions were made under a Rule 10b5-1 trading plan adopted on July 30, 2026.
Avalyn Pharma Inc. Chief Operating Officer Melissa Rhodes exercised options for 13,300 common shares at an exercise price of $4.62 per share on November 17, 2026, then sold 13,300 shares under a Rule 10b5-1 trading plan adopted July 30, 2026. The reported weighted-average sale prices were $27.7918 per share for 10,875 shares, $28.2069 per share for 2,025 shares, and $29.2286 per share for 400 shares. Her reported option position after exercise was 170,638 shares.
Douglas R. Carlson, Avalyn Pharma Inc. (AVLN)’s Chief Financial and Business Officer, exercised 14,875 stock options at a $4.62 exercise price on November 17, 2026, receiving common shares. His sales comprised 11,527 shares at a weighted average price of $27.7810, 3,093 at $28.2246, and 255 at $29.2267. The transactions were made under a Rule 10b5-1 trading plan adopted July 30, 2026. After the exercise, his reported stock-option position was 255,623 shares.
Avalyn Pharma Inc. (AVLN) officer Howard Lazarus reported a proposed sale of 53,200 common shares, with an aggregate market value of $1,583,232 and an approximate sale date of November 17, 2026. Lazarus's remarks state that the shares were and will be received upon exercise of stock options over the next three months, and list July 30, 2026, as the Rule 10b5-1 plan adoption date.
Avalyn Pharma Inc. (AVLN) director and officer Lyn Baranowski gave notice of a proposed sale of 210,000 common shares, with an aggregate market value of $6,249,600 and an approximate sale date of November 17, 2026.
Avalyn Pharma Inc. (AVLN) is named as issuer in officer Melissa Rhodes’s Form 144 notice of intended sale of 13,300 common shares, with an aggregate market value of $395,808 and an approximate sale date of November 17, 2026. The notice says Rhodes acquired the shares that day through exercise of stock options, with cash payment, and lists July 30, 2026, as the Rule 10b5-1 plan adoption or instruction date.
Avalyn Pharma Inc. (AVLN) officer Douglas Carlson reported a proposed sale of 14,875 common shares, with an aggregate market value of $442,680 and an approximate sale date of November 17, 2026. The notice says the shares were acquired from the issuer on November 17, 2026, through exercise of stock options, with cash payment.
Avalyn Pharma Inc. (AVLN) common stock held indirectly by F-Prime Capital Partners Healthcare Fund V LP was sold in four transactions reported by FMR LLC, a 10% owner. On November 9, 2026, the fund sold 173,661 shares at a weighted-average price of $29.06 and 1,339 shares at a weighted-average price of $29.75; on November 10, it sold 5,565 shares at a weighted-average price of $29.56 and 47,889 shares at a weighted-average price of $30.28. No Rule 10b5-1 plan is reported.
Avalyn Pharma Inc. reported a net loss of $29.655 million for the three months ended September 30, 2026, compared with $23.584 million a year earlier. Quarterly research and development expense was $25.491 million, versus $22.089 million, while general and administrative expense was $7.603 million, versus $3.234 million. For the first nine months of 2026, net loss was $85.459 million and cash used in operating activities was $82.237 million.
At September 30, 2026, cash, cash equivalents and marketable securities totaled $386.6 million. Avalyn stated these funds would be sufficient for operating expenses and capital expenditures for at least 12 months from issuance of the statements. Its May 1, 2026 IPO sold 19,166,667 shares at $18.00 per share and generated approximately $316.6 million in net proceeds. The company borrowed $15.0 million under a term loan facility of up to $30.0 million, with an additional $15.0 million available through December 31, 2027; the loan matures June 30, 2030.